Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562399 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL28175982 | 0.85 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5563238 | 0.81 | LTA4H (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL5563242 | 0.81 | LTA4H (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL5562044 | 0.78 | TAAR1 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2HTR2C | |
| SCHEMBL5562038 | 0.78 | TAAR1 (0.41) | SLC6A2SLC6A4SLC6A3KCNH2HTR2C | |
| SCHEMBL5562778 | 0.77 | CYP2D6 (0.54) | SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL5562773 | 0.77 | CYP2D6 (0.54) | SLC6A2SLC6A4CYP2D6 | |
| SCHEMBL27158577 | 0.76 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL27158374 | 0.76 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
| EP-1492794-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082877-A1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | SLC6A2 285/4885SLC6A4 168/4885SLC6A3 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.